Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMRA-301
- Development stage
- Preclinical
- Lead developer
- Damora Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
DMRA-301 is a preclinical biologic candidate, specifically a monoclonal antibody, being developed by Damora Therapeutics for the treatment of myeloproliferative neoplasms (MPNs), such as essential thrombocythemia and myelofibrosis. The drug is designed to selectively target the mutant form of calreticulin (CALR), which is characterized by a unique C-terminal neoepitope. In CALR-mutant MPNs, this mutant protein binds to and constitutively activates the thrombopoietin receptor (MPL), driving malignant cell proliferation. By binding to mutant CALR, DMRA-301 aims to disrupt the CALR-MPL interaction and eliminate mutant clones. Damora Therapeutics expects to file an Investigational New Drug (IND) application for its CALR-targeting programs in 2026.
Beyond the preview
Go deeper on DMRA-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMRA-301.